Bisphosphonates subcutaneous - Halozyme

Drug Profile

Bisphosphonates subcutaneous - Halozyme

Alternative Names: Bisphosphonate-PH20; Recombinant human hyaluronidase/bisphosphonates

Latest Information Update: 07 Jul 2009

Price : $50

At a glance

  • Originator Halozyme Therapeutics
  • Class Bisphosphonates; Glycoside hydrolases; Polysaccharide lyases; Recombinant proteins
  • Mechanism of Action Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Osteoporosis

Most Recent Events

  • 15 Dec 2008 Phase-I clinical trials in Osteoporosis in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top